Corcept Therapeutics Inc (NASDAQ: CORT)

$45.13 ▼ -1.21 (-2.61%)

As of Apr 21, 2026 03:59 PM

Sector: Healthcare Industry: Biotechnology CIK: 0001088856

Market Cap 4.57 Bn

P/E 46.27

P/S 6.00

Div. Yield 0.00

ROIC (Qtr) 0.10

Revenue Growth (1y) (Qtr) 11.12

Add ratio to table...

About

Corcept Therapeutics Inc is a commercial-stage company focused on the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company operates in the pharmaceutical industry, specifically targeting conditions such as hypercortisolism (Cushing's syndrome), various cancers, amyotrophic lateral sclerosis (ALS), and metabolic diseases like metabolic dysfunction-associated steatohepatitis (MASH). Corcept Therapeutics generates revenue...

Corcept Therapeutics Inc is a commercial-stage company focused on the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company operates in the pharmaceutical industry, specifically targeting conditions such as hypercortisolism (Cushing's syndrome), various cancers, amyotrophic lateral sclerosis (ALS), and metabolic diseases like metabolic dysfunction-associated steatohepatitis (MASH).

Corcept Therapeutics generates revenue primarily through the sale of its products, including Korlym and its authorized generic version, which are used to treat hypercortisolism. The company employs a direct sales force to reach physicians caring for patients with this condition, utilizing specialty pharmacies and distributors for logistical support. Additionally, Corcept Therapeutics is developing a portfolio of proprietary selective cortisol modulators, including relacorilant, nenocorilant, and dazucorilant, which are aimed at expanding its product offerings and addressing a broader range of medical conditions.

• Hypercortisolism (Cushing's syndrome): Corcept Therapeutics markets Korlym and its authorized generic version for the treatment of hypercortisolism. The company conducts educational programs to raise awareness about screening for this condition and the role of its products in treatment. Clinical studies such as the CATALYST and MOMENTUM trials aim to determine the prevalence of hypercortisolism in patients with difficult-to-control diabetes and resistant hypertension, respectively. These studies help physicians better identify patients with hypercortisolism and determine their optimal treatment.

• Oncology: Corcept Therapeutics is developing relacorilant in combination with chemotherapy for the treatment of various cancers, including platinum-resistant ovarian cancer. The company has submitted New Drug Applications (NDAs) and Marketing Authorization Applications (MAAs) for relacorilant plus nab-paclitaxel for this indication. Clinical trials such as ROSELLA and Phase 2 trials have shown promising results, with relacorilant demonstrating efficacy and a manageable safety profile. The company is also exploring the use of relacorilant in combination with androgen deprivation therapy for prostate cancer and nenocorilant in combination with immunotherapy for solid tumors.

• Amyotrophic Lateral Sclerosis (ALS): Corcept Therapeutics is developing dazucorilant as a potential treatment for ALS. The Phase 2 DAZALS trial did not meet its primary endpoint but showed a statistically significant reduction in early death. The company plans to initiate a pivotal Phase 3 trial for dazucorilant in 2026.

• Metabolic Diseases: Corcept Therapeutics is conducting a Phase 2b trial of miricorilant for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The MONARCH trial aims to reduce liver fat and improve liver health and key metabolic and lipid measures.

Corcept Therapeutics holds a unique position in the pharmaceutical industry by focusing on the modulation of cortisol effects, a mechanism that is not widely exploited by other companies. This specialized approach allows the company to target underserved medical conditions and potentially offer new treatment options for patients. The company's competitive advantages include a robust pipeline of selective cortisol modulators, a strong clinical trial portfolio, and strategic collaborations with academic research institutions. These factors position Corcept Therapeutics as a key player in the development of innovative therapies for complex disorders.

The company's customer base primarily consists of healthcare providers, including physicians who treat patients with hypercortisolism, various cancers, ALS, and metabolic diseases. Corcept Therapeutics also engages with specialty pharmacies and distributors to ensure the availability and logistical support of its products. The company's commitment to patient support programs and charitable foundations further strengthens its relationship with the medical community and patients.

Investment thesis

Bull case

Corcept’s recent guidance upgrade to $800 million through $850 million for the full year signals that market expectations have not yet fully absorbed the growing demand for its flagship product Korlym and the early pipeline momentum. The quarter’s 42.5 percent rise in tablet shipments and the continued record in the authorized generic segment demonstrate that the underlying sales engine is already operating at a scale that will support the revised revenue target. Management’s confidence is further bolstered by a strategic expansion of the specialty pharmacy network, with two additional partners slated to begin operations in early 2026, thereby eliminating the capacity bottleneck that constrained the previous vendor. Together, these factors indicate a strong upward trajectory that the current share price has not yet priced in.
The company’s robust sales force, now numbering 150 clinical specialists from an initial 60, has enabled deep penetration of the endocrinology market and accelerated prescriber engagement. A dedicated team focused on physician education is already translating emerging data from the CATALYST and MOMENTUM studies into increased awareness of hypercortisolism prevalence, creating a pipeline of new patients who may qualify for relacorilant once it receives approval. By positioning the company as the primary provider of cortisol modulation, Corcept is effectively creating a brand that can be leveraged across all therapeutic areas in its pipeline. This brand equity translates into a competitive moat that is difficult for other companies to replicate quickly.
The recent ROSELLA study results represent a breakthrough in the ovarian cancer space, with a 35 percent reduction in risk of death when relacorilant is added to nab‑paclitaxel. The trial’s 16.0 month median overall survival compared to 11.9 months for chemotherapy alone establishes the combination as a potential new standard of care in a field that has long struggled to achieve meaningful survival gains. Because relacorilant has oral administration and a well‑tolerated safety profile, the drug could be adopted rapidly by oncologists who currently rely on more toxic intravenous regimens. This therapeutic advantage is likely to translate into a significant share of the $20,000 to $30,000 annual treatment market in the United States alone.
The company’s orphan drug designation in the United States and Europe for both hypercortisolism and ovarian cancer provides an additional regulatory advantage that protects the product from generic competition for a minimum of 10 years. This exclusivity period ensures a period of monopoly pricing that can generate high gross margins, offsetting the incremental costs of commercialization. Furthermore, the authorization of a generic version at a 30 percent discount to the brand price suggests that Corcept is actively managing price sensitivity without sacrificing margin sustainability, a strategy that has already proven successful with Korlym.
Corcept’s strategic litigation against Teva over the Korlym generic is still in the appellate phase, and the court’s decision could potentially reinforce the company’s patent protection until 2037. If the appeal is successful, the company would effectively lock out generic competitors for nearly a decade, preserving the high net margin profile that has been the hallmark of the drug’s commercial performance. Even in the unlikely event that the appeal is denied, the current authorized generic volume is still around 75 percent of total sales, indicating that a transition to a lower priced product is already underway and will likely continue to drive incremental cash flow without significant margin erosion.

Corcept’s recent guidance upgrade to $800 million through $850 million for the full year signals that market expectations have not yet fully absorbed the growing demand for its flagship product Korlym and the early pipeline momentum. The quarter’s 42.5 percent rise in tablet shipments and the continued record in the authorized generic segment demonstrate that the underlying sales engine is already operating at a scale that will support the revised revenue target. Management’s confidence is further bolstered by a strategic expansion of the specialty pharmacy network, with two additional partners slated to begin operations in early 2026, thereby eliminating the capacity bottleneck that constrained the previous vendor. Together, these factors indicate a strong upward trajectory that the current share price has not yet priced in.
The company’s robust sales force, now numbering 150 clinical specialists from an initial 60, has enabled deep penetration of the endocrinology market and accelerated prescriber engagement. A dedicated team focused on physician education is already translating emerging data from the CATALYST and MOMENTUM studies into increased awareness of hypercortisolism prevalence, creating a pipeline of new patients who may qualify for relacorilant once it receives approval. By positioning the company as the primary provider of cortisol modulation, Corcept is effectively creating a brand that can be leveraged across all therapeutic areas in its pipeline. This brand equity translates into a competitive moat that is difficult for other companies to replicate quickly.
The recent ROSELLA study results represent a breakthrough in the ovarian cancer space, with a 35 percent reduction in risk of death when relacorilant is added to nab‑paclitaxel. The trial’s 16.0 month median overall survival compared to 11.9 months for chemotherapy alone establishes the combination as a potential new standard of care in a field that has long struggled to achieve meaningful survival gains. Because relacorilant has oral administration and a well‑tolerated safety profile, the drug could be adopted rapidly by oncologists who currently rely on more toxic intravenous regimens. This therapeutic advantage is likely to translate into a significant share of the $20,000 to $30,000 annual treatment market in the United States alone.
The company’s orphan drug designation in the United States and Europe for both hypercortisolism and ovarian cancer provides an additional regulatory advantage that protects the product from generic competition for a minimum of 10 years. This exclusivity period ensures a period of monopoly pricing that can generate high gross margins, offsetting the incremental costs of commercialization. Furthermore, the authorization of a generic version at a 30 percent discount to the brand price suggests that Corcept is actively managing price sensitivity without sacrificing margin sustainability, a strategy that has already proven successful with Korlym.
Corcept’s strategic litigation against Teva over the Korlym generic is still in the appellate phase, and the court’s decision could potentially reinforce the company’s patent protection until 2037. If the appeal is successful, the company would effectively lock out generic competitors for nearly a decade, preserving the high net margin profile that has been the hallmark of the drug’s commercial performance. Even in the unlikely event that the appeal is denied, the current authorized generic volume is still around 75 percent of total sales, indicating that a transition to a lower priced product is already underway and will likely continue to drive incremental cash flow without significant margin erosion.

Bear case

The FDA’s complete response letter for relacorilant in hypercortisolism indicates that the drug failed to meet the primary efficacy endpoint and raises serious liver safety concerns, with four patients experiencing probable drug‑induced liver injury. This regulatory setback suggests that the company will need to conduct additional trials to satisfy the agency, potentially delaying or preventing market entry for the drug’s flagship indication. The uncertainty around relacorilant’s approval timeline directly undermines the company’s projected $3 to $5 billion annual revenue from hypercortisolism over the next five years, casting doubt on the realism of those estimates.
Investor litigation alleging that the company misrepresented its regulatory interactions and the commercial potential of relacorilant signals a potential reputational crisis that could erode stakeholder confidence. The investigation by prominent law firms highlights the possibility of additional regulatory scrutiny and the risk of material adverse impact on the company’s valuation. A sustained loss of trust among investors could lead to higher cost of capital and restrict future financing options.
The increasing presence of generic competitors for Korlym, particularly with the authorized generic now accounting for 75 percent of total volume, threatens to erode the company’s gross margin. Management’s statement that margins will remain stable may be overly optimistic given the lower price point of the generic and the potential for further discounting as competition intensifies. Over time, margin compression could become a significant drag on profitability, especially if the company must lower prices to retain market share.
Corcept’s reliance on a single specialty pharmacy partner for the initial relacorilant launch introduces a bottleneck risk that could delay patient access and harm early adoption momentum. While the company plans to add additional pharmacies, the timeline for onboarding and scaling may not align with the FDA’s December 30 PDUFA deadline, potentially resulting in a lag between approval and widespread distribution. A delayed rollout would reduce the initial revenue window that is critical for recouping development costs.
The company’s pipeline concentration on glucocorticoid receptor antagonists, while innovative, creates a narrow therapeutic focus that could become a single point of failure if clinical outcomes fail to replicate in multiple indications. The high probability of attrition in early and late‑stage trials, combined with limited diversification outside this class, magnifies the risk that a failure in any key product could jeopardize the entire pipeline. This concentrated risk profile is a red flag for investors seeking more balanced portfolios.

The FDA’s complete response letter for relacorilant in hypercortisolism indicates that the drug failed to meet the primary efficacy endpoint and raises serious liver safety concerns, with four patients experiencing probable drug‑induced liver injury. This regulatory setback suggests that the company will need to conduct additional trials to satisfy the agency, potentially delaying or preventing market entry for the drug’s flagship indication. The uncertainty around relacorilant’s approval timeline directly undermines the company’s projected $3 to $5 billion annual revenue from hypercortisolism over the next five years, casting doubt on the realism of those estimates.
Investor litigation alleging that the company misrepresented its regulatory interactions and the commercial potential of relacorilant signals a potential reputational crisis that could erode stakeholder confidence. The investigation by prominent law firms highlights the possibility of additional regulatory scrutiny and the risk of material adverse impact on the company’s valuation. A sustained loss of trust among investors could lead to higher cost of capital and restrict future financing options.
The increasing presence of generic competitors for Korlym, particularly with the authorized generic now accounting for 75 percent of total volume, threatens to erode the company’s gross margin. Management’s statement that margins will remain stable may be overly optimistic given the lower price point of the generic and the potential for further discounting as competition intensifies. Over time, margin compression could become a significant drag on profitability, especially if the company must lower prices to retain market share.
Corcept’s reliance on a single specialty pharmacy partner for the initial relacorilant launch introduces a bottleneck risk that could delay patient access and harm early adoption momentum. While the company plans to add additional pharmacies, the timeline for onboarding and scaling may not align with the FDA’s December 30 PDUFA deadline, potentially resulting in a lag between approval and widespread distribution. A delayed rollout would reduce the initial revenue window that is critical for recouping development costs.
The company’s pipeline concentration on glucocorticoid receptor antagonists, while innovative, creates a narrow therapeutic focus that could become a single point of failure if clinical outcomes fail to replicate in multiple indications. The high probability of attrition in early and late‑stage trials, combined with limited diversification outside this class, magnifies the risk that a failure in any key product could jeopardize the entire pipeline. This concentrated risk profile is a red flag for investors seeking more balanced portfolios.

Class of Stock Breakdown of Revenue (2025)

Equity Components Breakdown of Revenue (2025)

Peer comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	111.34 Bn	28.15	9.28	-
2	REGN	Regeneron Pharmaceuticals, Inc.	78.06 Bn	17.30	5.44	1.99 Bn
3	ALNY	Alnylam Pharmaceuticals, Inc.	41.92 Bn	152.39	13.31	-
4	RVMD	Revolution Medicines, Inc.	28.36 Bn	-25.11	34,170.56	-
5	ZLAB	Zai Lab Ltd	25.77 Bn	-147.06	106.30	0.20 Bn
6	MESO	Mesoblast Ltd	24.32 Bn	-190.54	1,414.27	0.12 Bn
7	MRNA	Moderna, Inc.	21.25 Bn	-7.52	10.93	0.59 Bn
8	RPRX	Royalty Pharma plc	20.83 Bn	27.08	8.76	8.95 Bn

Research Tools